Xinlay Phase III Back-Up Trial Winding Down
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott expects to have data by year-end on which to base a regulatory strategy for the prostate cancer drug.
You may also be interested in...
Taxotere Could Get Boost From NICE Prostate Cancer Nod
U.K.’s National Institute for Health & Clinical Excellence recommends coverage of Sanofi-Aventis’ docetaxal for hormone-refractory metastatic prostate cancer.
Taxotere Could Get Boost From NICE Prostate Cancer Nod
U.K.’s National Institute for Health & Clinical Excellence recommends coverage of Sanofi-Aventis’ docetaxal for hormone-refractory metastatic prostate cancer.
Abbott Receives Xinlay “Not Approvable” Letter
Letter follows a unanimous recommendation by FDA’s Oncologic Drugs Advisory Committee against approving atrasentan for treatment of hormone refractory prostate cancer in patients with disease metastatic to bone.